BioNexus Gene Lab (BGLC) Competitors

$0.57
0.00 (0.00%)
(As of 05/17/2024 ET)

BGLC vs. OPGN, PMD, DMTK, XGN, BTCY, MBRX, AEZS, BCDA, GHSI, and PHXM

Should you be buying BioNexus Gene Lab stock or one of its competitors? The main competitors of BioNexus Gene Lab include OpGen (OPGN), Psychemedics (PMD), DermTech (DMTK), Exagen (XGN), Biotricity (BTCY), Moleculin Biotech (MBRX), Aeterna Zentaris (AEZS), BioCardia (BCDA), Guardion Health Sciences (GHSI), and PHAXIAM Therapeutics (PHXM). These companies are all part of the "medical" sector.

BioNexus Gene Lab vs.

BioNexus Gene Lab (NASDAQ:BGLC) and OpGen (NASDAQ:OPGN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, community ranking, earnings, profitability, risk, media sentiment and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioNexus Gene Lab
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
OpGen
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

BioNexus Gene Lab has a net margin of -27.24% compared to OpGen's net margin of -852.18%. BioNexus Gene Lab's return on equity of -30.74% beat OpGen's return on equity.

Company Net Margins Return on Equity Return on Assets
BioNexus Gene Lab-27.24% -30.74% -25.41%
OpGen -852.18%-316.30%-89.52%

OpGen received 301 more outperform votes than BioNexus Gene Lab when rated by MarketBeat users.

CompanyUnderperformOutperform
BioNexus Gene LabN/AN/A
OpGenOutperform Votes
301
55.74%
Underperform Votes
239
44.26%

BioNexus Gene Lab has higher revenue and earnings than OpGen.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioNexus Gene Lab$9.77M1.04-$2.63MN/AN/A
OpGen$3.07M1.89-$37.28M-$6.51-0.07

In the previous week, OpGen had 4 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 5 mentions for OpGen and 1 mentions for BioNexus Gene Lab. OpGen's average media sentiment score of -0.22 beat BioNexus Gene Lab's score of -0.95 indicating that OpGen is being referred to more favorably in the news media.

Company Overall Sentiment
BioNexus Gene Lab Negative
OpGen Neutral

18.9% of BioNexus Gene Lab shares are owned by institutional investors. Comparatively, 2.7% of OpGen shares are owned by institutional investors. 6.8% of BioNexus Gene Lab shares are owned by company insiders. Comparatively, 1.3% of OpGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

BioNexus Gene Lab beats OpGen on 7 of the 11 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGLC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BGLC vs. The Competition

MetricBioNexus Gene LabMedical laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$10.14M$2.34B$5.24B$7.99B
Dividend YieldN/A1.81%44.24%3.91%
P/E RatioN/A11.29103.2115.05
Price / Sales1.04129.142,370.1481.39
Price / CashN/A374.5236.7931.98
Price / Book1.083.795.494.64
Net Income-$2.63M-$135.88M$105.95M$217.28M
7 Day Performance-1.10%0.66%1.42%2.90%
1 Month Performance-4.32%7.55%4.96%6.66%
1 Year PerformanceN/A-6.39%7.84%9.89%

BioNexus Gene Lab Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OPGN
OpGen
0 of 5 stars
$0.44
flat
N/A-33.5%$5.55M$2.61M-0.0785Upcoming Earnings
Analyst Forecast
Stock Split
News Coverage
PMD
Psychemedics
0.3613 of 5 stars
$2.65
+3.9%
N/A-48.3%$15.40M$22.10M-3.68116Earnings Report
News Coverage
DMTK
DermTech
0.5989 of 5 stars
$0.62
flat
$2.38
+283.3%
-79.8%$21.46M$15.30M-0.20206Positive News
XGN
Exagen
4.8967 of 5 stars
$1.64
+4.5%
$6.00
+265.9%
-40.3%$28.47M$52.55M-1.22174Analyst Forecast
Analyst Revision
News Coverage
Positive News
High Trading Volume
BTCY
Biotricity
0 of 5 stars
$1.09
-11.4%
N/AN/A$10.27M$9.64M-0.7855News Coverage
Gap Up
MBRX
Moleculin Biotech
2.0611 of 5 stars
$4.67
-1.9%
$35.00
+649.5%
-46.9%$10.41MN/A0.0018Analyst Forecast
Analyst Revision
News Coverage
AEZS
Aeterna Zentaris
2.2689 of 5 stars
$8.40
+2.1%
$60.00
+614.4%
-25.1%$10.16M$4.50M-0.6211Analyst Forecast
News Coverage
High Trading Volume
BCDA
BioCardia
2.1434 of 5 stars
$0.39
flat
$4.00
+922.5%
-76.9%$10.51M$480,000.00-0.7116Earnings Report
GHSI
Guardion Health Sciences
0 of 5 stars
$8.22
flat
N/A+35.3%$10.52M$12.25M74.739Upcoming Earnings
Positive News
PHXM
PHAXIAM Therapeutics
0 of 5 stars
$3.10
flat
N/AN/A$10.58M$32.66M0.0049

Related Companies and Tools

This page (NASDAQ:BGLC) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners